All Oncology News

Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.

Sarah K. Tasian, MD, discusses the diagnostic and therapeutic approaches to treating patients with pediatric Philadelphia-like acute lymphoblastic leukemia.

The FDA has added 3 months to the review period for the combination of nivolumab plus low-dose ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Diana L. Hanna, MD, discusses the past, present, and future of treatment for patients with metastatic pancreatic cancer.

Igor Puzanov, MD, MSCI, FACP, discusses the current and potential future utility of talimogene laherparepvec (T-VEC; Imlygic) in patients with advanced-stage melanoma.

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses the shifting landscape of nonmetastastic CRPC, along with other developments across the prostate cancer paradigm.

Ruth O’Regan, MD, discusses the excitement with biosimilars and the potential impact they could have on the US drug market.

Combining the PD-1 inhibitor pembrolizumab with the VEGF inhibitor axitinib significantly improved survival versus sunitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

Vivian G. Oehler, MD, discusses the diagnosis, risk prognostication and therapeutic strategies for polycythemia vera, essential thrombocytopenia, and myelofibrosis.

A new drug application has been submitted to Japan's Ministry of Health, Labor and Welfare for quizartinib for the treatment of adult patients with FLT3-ITD–positive acute myeloid leukemia.

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA has granted olaparib an orphan drug designation for the treatment of patients with pancreatic cancer.

The FDA has approved talazoparib (Talzenna) for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.

Ado-trastuzumab emtansine (T-DM1; Kadcyla) was found to significantly reduce the risk of disease recurrence or death compared with trastuzumab (Herceptin) as an adjuvant treatment in patients with HER2-positive early breast cancer who have residual disease following neoadjuvant therapy.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options.

A. Jo Chien, MD, discusses emerging agents and other developments in HER2-positive breast cancer.

Single-agent nivolumab (Opdivo) did not improve overall survival compared with standard topotecan or amrubicin, where approved, in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.

Gilberto Lopes, MD, discusses the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.

Mary-Beth Percival, MD, discusses the ongoing development of FLT3 inhibitors and other current research in patients with AML.

Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

Laura J. Esserman, MD, MBA, discusses the goals of the I-SPY trials and their impact thus far on patients with high-risk early breast cancer.

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 recommending approval of the rituximab biosimilar CT-P10 for 3 non-Hodgkin lymphoma indications.

Hope S. Rugo, MD, discusses the highly anticipated studies of immunotherapy in triple-negative breast cancer and where the class of agents optimally fits in the landscape.

Michael Green, MD, discusses treatment strategies following early relapse in multiple myeloma.

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.

Nina Shah, MD, discusses the present and future of chimeric antigen receptor T-cell therapy in myeloma.

Chaitra S. Ujjani, MD, discusses the latest progress in both Hodgkin lymphoma and mantle cell lymphoma.

Brian Till, MD, discusses the rapidly evolving field of chimeric antigen receptor (CAR) T cells.

Among new advances in multiple myeloma, high-dose chemotherapy and allogeneic stem cell transplant remain the go-to frontline treatment for patients with newly diagnosed multiple myeloma.

Mazyar Shadman, MD, MPH, discusses the evolution of therapy in CLL and how physicians are working to balance novel agents with additional modalities.